KalVista Pharmaceuticals (NASDAQ:KALV) Stock Rating Lowered by Wall Street Zen
by Jessica Moore · The Cerbat GemKalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
KALV has been the subject of several other research reports. Needham & Company LLC upped their price target on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. HC Wainwright upped their price target on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Stifel Nicolaus upped their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Finally, Citizens Jmp cut their target price on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Thursday, March 26th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.
View Our Latest Research Report on KalVista Pharmaceuticals
KalVista Pharmaceuticals Stock Up 0.7%
Shares of NASDAQ:KALV opened at $19.56 on Tuesday. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The company has a market cap of $1.00 billion, a PE ratio of -4.95 and a beta of -0.40. KalVista Pharmaceuticals has a 52 week low of $9.83 and a 52 week high of $21.31. The firm has a 50 day simple moving average of $17.67 and a 200 day simple moving average of $15.31.
Insider Buying and Selling
In other KalVista Pharmaceuticals news, CFO Brian Piekos sold 1,862 shares of the stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $37,649.64. Following the completion of the sale, the chief financial officer owned 18,150 shares in the company, valued at $366,993. This represents a 9.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Nicole Sweeny sold 1,862 shares of the stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $20.22, for a total transaction of $37,649.64. Following the completion of the sale, the insider owned 51,391 shares of the company’s stock, valued at approximately $1,039,126.02. The trade was a 3.50% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 263,969 shares of company stock worth $4,536,178. Insiders own 4.30% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in shares of KalVista Pharmaceuticals by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock valued at $30,464,000 after purchasing an additional 88,720 shares in the last quarter. Tudor Investment Corp ET AL bought a new position in shares of KalVista Pharmaceuticals during the 3rd quarter valued at $24,360,000. State Street Corp raised its holdings in shares of KalVista Pharmaceuticals by 21.3% during the 4th quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company’s stock valued at $30,874,000 after purchasing an additional 336,195 shares in the last quarter. Vestal Point Capital LP raised its holdings in shares of KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after purchasing an additional 1,140,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC raised its holdings in shares of KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after purchasing an additional 1,055,940 shares in the last quarter.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.